1.
Clin Exp Dermatol
; 34(3): 418-20, 2009 Apr.
Artículo
en Inglés
| MEDLINE
| ID: mdl-19120387
2.
Clin Exp Dermatol
; 33(4): 437-9, 2008 Jul.
Artículo
en Inglés
| MEDLINE
| ID: mdl-18485021
RESUMEN
Infliximab is a tumour necrosis factor (TNF)-alpha blocking drug classified as a biological response modifier. It has been suggested that the risk of malignancies, especially lymphomas, is increased in patients with rheumatoid arthritis (RA) treated with anti-TNF-alpha antibody therapy. We present a case of malignant lymphoma during the treatment of RA with infliximab and methotrexate.